How GLP-1 Drugs Actually Work

The Natural Hormone

GLP-1 (glucagon-like peptide-1) is a 30-amino-acid incretin hormone secreted by intestinal L-cells within minutes of eating. It coordinates the body's metabolic response to food through four simultaneous effects: glucose-dependent insulin release from pancreatic β-cells (only when blood sugar is elevated — critical for avoiding hypoglycemia), suppression of glucagon from α-cells (reducing hepatic glucose output), slowed gastric emptying (prolonging post-meal satiety), and appetite reduction via hypothalamic POMC/CART neuron activation and NPY/AgRP inhibition in the arcuate nucleus.

This combination of effects makes GLP-1 one of the most therapeutically valuable hormones in the human body. It simultaneously controls blood sugar, reduces appetite, and coordinates the entire digestive response to a meal. The only problem: the enzyme dipeptidyl peptidase-4 (DPP-4) destroys native GLP-1 in approximately 2 minutes, making the natural hormone completely impractical as a drug. The entire history of GLP-1 pharmacology has been about solving this half-life problem — and each generation of solutions has produced incrementally better clinical outcomes.

The Engineering Solutions

Exenatide (2005): The first GLP-1 drug — and its origin is one of the best stories in pharmaceutical history. Endocrinologist John Eng discovered a peptide in Gila monster venom (exendin-4) that activated human GLP-1 receptors but was naturally resistant to DPP-4 degradation. The lizard had already solved the half-life problem through evolution. Exenatide's half-life of 2.4 hours enabled twice-daily dosing. It proved the GLP-1 concept and opened the door for everything that followed.

Liraglutide (2010): Novo Nordisk's first long-acting GLP-1 — and the innovation that made the company the dominant force in incretin therapeutics. By attaching a C16 fatty acid (palmitic acid) to the GLP-1 molecule, they enabled non-covalent binding to serum albumin in the bloodstream. This shielded liraglutide from degradation and extended the half-life to 13 hours — enabling once-daily dosing. Marketed as Victoza (diabetes) and Saxenda (weight loss, producing ~5-8% weight loss).

Semaglutide (2017): The breakthrough. Novo Nordisk refined the liraglutide approach with three modifications: Aib at position 8 blocks DPP-4 cleavage, Arg34 prevents wrong-site fatty acid attachment, and a C18 fatty diacid via mini-PEG linker provides stronger albumin binding. Result: half-life of approximately 7 days, enabling once-weekly injection. In the STEP trials, Wegovy (2.4 mg weekly) produced 15-17% weight loss — a leap that transformed obesity from an untreatable condition to a pharmaceutical target. Semaglutide also became the first oral GLP-1 (Rybelsus), using a SNAC permeation enhancer to achieve ~1% oral bioavailability.

Tirzepatide (2022): Eli Lilly's dual agonist changed the paradigm by targeting two receptors with one molecule — GLP-1R plus GIP receptor. Built on a GIP backbone with engineered GLP-1R cross-reactivity and a C20 fatty diacid for albumin binding. SURMOUNT trials showed 22.5% weight loss at the highest dose — the most effective single-agent obesity drug ever approved.

Retatrutide (Phase III): The next frontier — a triple agonist adding glucagon receptor activation to GLP-1/GIP. Glucagon drives hepatic lipid oxidation and thermogenesis, increasing energy expenditure (calories burned) alongside the appetite suppression from GLP-1. Phase II showed 24.2% weight loss at 48 weeks, with the curve not yet plateaued. Phase III results expected 2026-2027.

Why They Cause Weight Loss

The weight loss mechanism is primarily appetite suppression — GLP-1 receptor activation in the hypothalamus reduces hunger signals, food cravings, and the hedonic (pleasure-driven) motivation to eat. Neuroimaging studies show reduced brain reward center activation in response to food cues. Patients consistently describe a fundamental shift in their relationship with food: they feel full sooner, think about food less, and lose the compulsive eating patterns that made previous weight loss attempts unsustainable.

This is not a "metabolism boost" — semaglutide and tirzepatide work primarily by reducing caloric intake, not by increasing calories burned. (Retatrutide is the exception: its glucagon component does increase energy expenditure.) Slowed gastric emptying also contributes — food stays in the stomach longer, prolonging satiety and reducing post-meal glucose spikes.

The critical clinical reality: weight returns when you stop. The STEP 1 extension demonstrated that approximately two-thirds of lost weight was regained within one year of discontinuing semaglutide. This is not a failure of the drug — it reflects the biology of obesity. GLP-1 drugs suppress the hormonal and neurological drivers of weight gain. When the drug is removed, those drivers reassert themselves. This means GLP-1 drugs treat obesity as a chronic condition requiring ongoing medication, analogous to how statins manage cholesterol or antihypertensives manage blood pressure. Whether lifelong pharmacotherapy for obesity is the right approach is one of the most important questions in medicine today.